Post Market Surveillance Study to Confirm Safety and Performance of Silicone PHMB Foam

Advanced Medical Solutions Ltd.187 enrolled

Overview

Post market surveillance study to confirm the safety and performance of Silicone Subcategory of PHMB Foam Dressings in Chronic and Acute Wounds.

The design of the study is an open label, multicentre, single arm trial with subjects with moderate to heavily exuding chronic and acute wounds consisting of pressure ulcers, leg ulcers, diabetic leg and foot ulcers, surgical wounds first degree superficial and partial thickness burns. The performance data from this study will support clinically meaningful rates of successful improvement in the signs and symptoms of infection, without refection during 6- week treatment and follow up period.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

187

Conditions

Wound

Interventions

ActivHeal Silicone PHMB Foam Adhesive and Non Adhesive dressing.DEVICE

Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with ActivHeal Silicone PHMB Foam adhesive and Non Adhesive Foam dressings. Subjects will be evaluated as follows: Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change over a four - six-week period (per AMS Product) or until the wound is healed to extent that the use of the ActivHeal Silicone PHMB Foam adhesive and Non Adhesive Foam dressings. is no longer indicated from the time that the patient has been recruited. The assessment of the presence and reduction of the signs and symptoms of Infection.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Have a pressure ulcer, leg ulcer, diabetic leg and foot ulcer, surgical wound, first degree superficial burns or partial thickness second degree burns that are infected following assessment of signs and symptoms of infection with moderate to heavy levels of exudate. * Have wounds at high risk of infection. * Males or females, age 18 years or above. * Subjects who are able to understand and give informed consent to take part in the study. Exclusion Criteria: * Subjects who are known to be non compliant with medical treatment. * Subjects who are known to be sensitive to any of the device components, known sensitivity to PHMB. * Subject is pregnant or actively breastfeeding. * Subject has any significant or unstable medical or psychiatric condition, that in the opinion of the investigator, would interfere with his/her ability to participate in the study. * Subject is currently in another clinical study. * Patients who have a current illness or condition, or who have had an illness in the last 30 days which in the opinion of the investigator may interfere with wound healing (e.g. carcinoma, connective tissue disease, autoimmune disease or alcohol or drug abuse). * Life expectancy of \<6 months. * Maximum burn area of \>20% total body area in adults.

Locations (3)

Dr Thirumani Govender

Bellville, Cape Town, South Africa

Delft Day Hospital Premises

Delft S., Cape Town, South Africa

Brooklyn Chest Hospital

Ysterplaat, Cape Town, South Africa

Outcomes

Primary Outcomes

Effectiveness of the ActivHeal Silicone PHMB foam adhesive and Non Adhesive foam dressing

Effectiveness (performance) of the ActivHeal Silicone PHMB will be evaluated for efficacy success according to the following success criteria: Reduction in signs and symptoms of infection from baseline as defined as * The change from the Investigator's opinion of infection being present to no longer being present, or * If the Investigator determines infection is still present there is improvement in severity of at least two. No worsening of any signs/ symptoms of infection at 6 weeks or if infection resolved prior to 6 weeks, that no new evidence of infection occurred during the 6 week treatment follow up.

Time frame: Immediately following initial assessment, dressing removal every 7 days follow up visits, for 6 weeks.

Secondary Outcomes

Safety of the ActivHeal Silicone PHMB foam adhesive and Non Adhesive foam dressing.

Safety will evaluated as incidence of device related adverse events.

Time frame: Immediately following initial assessment, dressing removal every 7 days follow up visits, for 6 weeks.

Effectiveness of the ActivHeal Silicone PHMB foam adhesive and Non Adhesive foam dressing in terms of wound progression

Wound progression, assessed as the change from baseline to end of follow up. Monitoring of tissue types %,decrease in devitalised tissue, size and depth of wound.

Time frame: Immediately following initial assessment, dressing removal every 7 days follow up visits, for 6 weeks.

Effectiveness of the ActivHeal Silicone PHMB foam adhesive and Non Adhesive foam dressing in terms of pain.

Change in patient pain will be assessed using Visual Analogue Scale, VAS, from baseline to end of follow up. Pain will assessed by completion of a Visual Analogue Scale VAS (0= no pain to 10 = worst pain imaginable).

Time frame: Immediately following initial assessment, dressing removal every 7 days follow up visits, for 6 weeks.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.